diffuse normolipemic plane xanthoma ( dnpx ) was first described by altman and winkelmann in 1962 . the features of this entity are : ( 1 ) xanthelasma palpebrarum ; ( 2 ) diffuse xanthoma planum of the head , neck , trunk , and extremities , and ( 3 ) plasma lipid values that are within normal limits . several associations have been reported between dnpx and lymphoproliferative and myeloproliferative disorders , particularly multiple myeloma and benign monoclonal gammopathy ( often iga ) [ 2 , 3 ] . all therapeutic options for the treatment of plane xanthoma include mechanical removal by excision , chemabrasion , dermabrasion , or abrasive laser therapy [ 4 , 5 , 6 ] . we report on a patient with dnpx who received oral probucol and showed significant clearing of the lesions . a 70-year - old woman presented with well - defined macular yellowish patches on her eyelids , both cheeks , and the nose lasting over a few years ( fig . 1 ) . she had no history of topical steroid use or extensive sun exposure on her face . a skin biopsy specimen revealed the accumulation of foam cells and touton giant cells in the superficial dermis ( fig . complete blood count , and liver and renal function tests were within normal limits , but she had elevated levels of iga [ 460.7 mg / dl ( normal values : 100400 mg / dl ) ] and amylase [ 270 iu / l ( normal values : 40120 plasma lipid levels including total cholesterol , hdl and ldl cholesterols , triglycerides , and apolipoproteins were normal . she was diagnosed with idiopathic macroamylasemia and treatment was considered unnecessary . based on the clinical and histopathological findings , a diagnosis of dnpx was made and oral administration of probucol ( 500 mg / day ) was initiated . the lesions began to recede after 2 weeks and had almost resolved within 8 months ( fig . dnpx , first described in 1962 , is characterized by diffuse , yellow to orange , slightly elevated plaques with sharply delineated borders that may affect any part of the body . type i contains patients with xanthomas found in association with an altered lipoprotein content or structure . type iii consists of patients with neither lipoprotein abnormalities nor underlying systemic disease , but in whom local tissue alterations seem to play a role in xanthoma formation . lesions can be removed by excision , chemabrasion , dermabrasion , or abrasive laser therapy [ 4 , 5 , 6 ] . lorenz et al .   used an er : yag laser for full - face dnpx lesions under general anesthesia and reported that the lesions were almost completely removed after 2 sessions . although these excisional or abrasive therapies may be useful for limited lesions including palpebral xanthelasmas , they may be too invasive for widespread lesions . probucol is an antioxidant that may inhibit atherogenesis by limiting the oxidative modification of ldl cholesterol [ 8 , 9 ] and , thus , foam cell formation and/or endothelial cell injury . .   showed that xanthelasma lesions decreased in size in their 7 cases , and 3 lesions disappeared during probucol therapy in patients with hypercholesterolemia . furthermore , 17 out of 25 xanthelasma patients ( 68% ) with normolipemia exhibited regression after taking probucol . therefore , we used probucol to treat our patient with dnpx . the results obtained were remarkable , and we suggest that probucol be included as a primary therapy for dnpx .